The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
|Videos|February 20, 2019
KRAS-Mutated Metastatic CRC
KRAS-Mutated Metastatic CRC
Advertisement
Case: A 38-year Old Woman WithKRAS-Mutated mCRC
Initial presentation
- A 38-year old woman was referred to gastroenterology after experiencing several bouts of bloody diarrhea
- PMH: unremarkable
- PE: unremarkable
Clinical workup
- Colonoscopy: suspicious sigmoid mass, partial obstruction
- Biopsy: poorly differentiated adenocarcinoma
- Imaging: CT scan of the chest/abdomen/pelvis revealed multiple small bilateral liver metastases
- Molecular testing on tissue biopsy:
- Positive forKRASexon 2 codon 12 mutation
- Negative forNRAS,BRAF
- Microsatellite-stable
- Diagnosis: stage IV colorectal cancer
- ECOG PS 0
Treatment
- She underwent laparoscopic sigmoid resection
- She was initiated on treatment with FOLFOX + bevacizumab; well-tolerated
- Follow-up imaging at 3 and 6 months showed a partial response
Advertisement
Related to this article
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5